Compare FMC Corp (FMC) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Eli Lilly And Co — how do they compare? FMC Corp trades at $8.89 (market cap $1.41B), while Eli Lilly And Co trades at $1,167.38 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 737.6× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.52%). Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Eli Lilly And Co for 93 Days on average.
| FMC | LLY | |
|---|---|---|
Market Cap | $1.41B | $1.04T |
Volume | 4,507,459 | 3,064,878 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $1.28K |
52-Week Low | $8.44 | $799.57 |
Typical Hold Time | 68 Days | 93 Days |
Enterprise Value | $5.22B | $1.09T |
Dividend Yield | 3.52% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.92, down 1.22% on the day, with a bearish technical signal and negative profitability metrics including a net income margin of -84.83% and ROE of -91.47% for 2025. Recent news highlights regulatory progress with rimisoxafen in Brazil and a minority equity investment from Tessenderlo Group. Cash flow trends show volatility, with 2025 net cash flow positive at $227.20M but driven by financing activities as operating cash flow was negative.
The outlook is challenged by significant losses and high debt, though analyst consensus suggests upside with a $14.60 price target. Key risks include sustained negative margins, industry cyclicality, and execution of deleveraging plans. The stock presents a high-risk opportunity contingent on operational turnaround and debt reduction success.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
